William J. Rieflin
Chief Executive Officer
Mr. Rieflin joined NGM as Chief Executive Officer in 2010 and brings over 20 years of industry experience to the company. Most recently, he was President of XenoPort, Inc. (NASDAQ: XNPT). Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. He currently serves on the Board of Directors of Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), FLX Bio, Inc. and XenoPort. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.
Prior to joining NGM in 2014, Mr. Jonker was the Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to the spin-out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG) and leadership positions in the business development and legal groups at Genentech. Prior to Genentech, he was an associate in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.
Jin-Long Chen, Ph.D.
Founder And Chief Scientific Officer
Dr. Chen is the Company's Founder, and has served as a member of the board of directors and as the Chief Scientific Officer since January 2008. He was also NGM's President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company's global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen's pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including RepathaTM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.
Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Prof. Robert Tjian.
Vice President, Chief Medical Officer
Prior to joining NGM in 2010, Dr. DePaoli was CMO at InteKrin Therapeutics. In this role he oversaw global development of INT131, a PPARg modulator, through a successful End of Phase 2 meeting with the FDA. He brings to NGM more than 20 years of experience as a clinician and translational researcher in diabetes, obesity and metabolic disease. Dr. DePaoli trained in Clinical and Molecular Endocrinology at the University of Chicago and in the Howard Hughes laboratory of Dr. Graham Bell. His clinical and translational research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute which led him to join Amgen in 1998 to champion the development of their cardiometabolic disease portfolio. His work at Amgen was pivotal in enabling multiple clinical applications of the adipocytokine leptin (Myalept). At Amgen, he also led a broad array of cardiometabolic, muscle and bone programs with a focus on translating novel pathways into the clinic. These pathways included: RANK Ligand (now Prolia and Xgeva), PCSK9 (Evolocumab), 11 Beta HSD-1, Myostatin, IL-1 receptor, Calcium Sensing Receptor (Sensipar), PPAR-gamma modulation, DPP-4 and MCH-R1. Dr. DePaoli also maintains a clinical endocrinology practice at the William Sansum Diabetes Center.
Marc Learned, Ph.D.
VICE PRESIDENT, RESEARCH OPERATIONS
Dr. Learned joined NGM as the Director of Research Operations in January 2008, providing strategic and operational support for the Company’s research efforts. Formerly a Director of Research in Metabolic Disorders at Amgen, he led in vivo pharmacology for several programs and played a significant operational role in the department. Previously, he was part of the Lead Discovery group at Tularik and was central to the identification and optimization of lead compounds for multiple projects in the diabetes and obesity programs, including several candidates selected for human clinical studies. Dr. Learned graduated from the University of California, Los Angeles with a B.S. in Biochemistry and received a Ph.D. in biochemistry from the University of California, Berkeley. He completed post-doctoral training at the Whitehead Institute for Biomedical Research, and subsequently served as an Assistant Professor in the Department of Biochemistry at the University of California, Davis.
Wenyan (David) Shen, Ph.D.
VICE PRESIDENT, BIOLOGICS AND CMC
Dr. Shen is a leading expert with more than 20 years of experience in the antibody and therapeutic protein field, and has a proven record of advancing pipelines from discovery to proof-of-concept in clinical stage to registration. Dr. Shen joined NGM in 2013 and was most recently Vice President, Global Head of Biologics Development at TEVA Pharmaceuticals and managed the innovative biologics, biobetters and biosimilars portfolio across therapeutic areas. During his tenure, several biologics/biosimilars were successfully approved, including TBO-Filgrastim by FDA and Lipegfilgrastim by EMA. Prior to TEVA, Dr. Shen was Executive Director, Biologics Research and GlycoFi at Merck where he oversaw overall biologics pipeline from discovery to preclinical development. His professional career started at Amgen where he held positions of increasing responsibility, including site-head for the Protein Sciences Department in San Francisco, and was critical in advancing more than eight antibody drug candidates from research to clinical development and regulatory approval, including evolucumab (anti-PCSK9), romosozumab (anti-sclerostin) and denosumab (anti-RANKL). In addition, he has developed the mammalian full IgG display technology that is now widely used by the antibody field. Dr. Shen graduated from East China University of Science and Technology and received a Ph.D. from University of Toronto. He completed post-doctoral training at the Whitehead Institute for Biomedical Research.
Hui Tian, Ph.D.
Vice President, Research
Dr. Tian joined NGM in January 2008, providing leadership for the Company’s discovery research efforts. He was most recently the Scientific Director in the Metabolic Disorders Therapeutic Area at Amgen, responsible for early stage discovery research in the area of diabetes and lipid disorders. Prior to Amgen, he was responsible for the orphan G protein-coupled receptor drug discovery program at Tularik, successfully leading several projects in multiple therapeutic areas, including metabolic disease, inflammation and neurodegenerative disorders. During the course of these efforts, Dr. Tian and his team identified several clinical candidates for study in humans. Dr. Tian received a Ph.D. in Molecular and Cellular Biology at the University of Texas Southwestern Medical Center and completed post-doctoral training in Developmental Biology at Harvard University.
Aetna Wun Trombley, Ph.D.
Chief Operating Officer
Dr. Trombley joined NGM as head of Business Development in 2011 and became our Chief Operating Officer in 2015. She was most recently from Novartis in Basel, Switzerland, where she was Chief of Staff for the Chief Executive Officer and worked on key corporate initiatives and strategic projects across the company’s healthcare businesses. Previously, she was Associate Director, Business Development at XenoPort, Inc. (NASDAQ: XNPT), where her responsibilities also included strategic and portfolio planning in addition to various out-licensing projects. Prior to XenoPort, she was a Senior Engagement Manager at McKinsey & Company, where she advised pharmaceutical and medical device clients on strategic, commercial and operational issues. She received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from MIT.
David Woodhouse, Ph.D.
Chief Financial Officer
Dr. Woodhouse joined NGM in 2015 from Goldman Sachs where he was a managing director and co-head of U.S. biotechnology investment banking. As a member of Goldman's healthcare investment banking group for nearly 13 years in both the New York and San Francisco offices, his responsibilities included corporate finance and mergers and acquisitions advice for the biotechnology, specialty pharma and diagnostics industries. In this capacity, he advised on several billion in equity and equity-linked financings as well as over $90 billion in M&A transactions.
Prior to Goldman Sachs, Dr. Woodhouse worked in various business development and research roles at Dynavax and Amgen. He graduated, with highest honors, from UC Santa Barbara, with a B.A. in Pharmacology. He also earned a Ph.D. in Molecular Pharmacology from Stanford University School of Medicine and an M.B.A. from the Tuck School of Business at Dartmouth.